Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mosaic sosips
- Development stage
- Phase 1
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Mosaic SOSIPs are engineered HIV-1 envelope glycoprotein (Env) trimer-based immunogens designed to present a diverse array of epitopes from multiple HIV strains. They are used as vaccine candidates to elicit broad and potent antibody responses targeting conserved regions of the virus, with the goal of inducing broadly neutralizing antibodies (bNAbs). These constructs are typically formulated as nanoparticles for improved immunogenicity and stability. In preclinical studies, mosaic SOSIPs have shown enhanced induction of antigen-specific B cells and antibody responses compared to single-strain or simple cocktail formulations[1].
- Other names
- mosaic HIV-1 glycoprotein nanoparticlesmosaic SOSIP nanoparticles
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on mosaic sosips.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mosaic sosips.